Stryker Corp.

SYK-N

Get Alerts55 watching

NYSE:SYK

214.60
0.37 (0.17%)
Stryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and ...
More at Wikipedia
SYK Fundamental Data  by TradingView
SYK Chart  by TradingView
Technical Analysis for SYK  by TradingView

Analysis and Opinions about SYK-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
January 20, 2020
(A Top Pick Jan 04/19, Up 21%) The best, most innovative medical device company around. It's come off its highs recently as it acquired a spinal business, but it has room to run. It's long grown its earnings for many years. They excel at buying small companies specializing in hips, knees and spines.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
January 20, 2020
(A Top Pick Jan 04/19, Up 21%) The best, most innovative medical device company around. It's come off its highs recently as it acquired a spinal business, but it has room to run. It's long grown its earnings for many years. They excel at buying small companies specializing in hips, knees and spines.
biotechnology/pharmaceutical
0 Comments
John O'Connell, CFA

Unlock Ratings

Price
$212.170
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
January 17, 2020
A diversified medical devices company. They create a variety of equipment, including orthopaedics and robotic surgery. The company has executed very well. They recently made an acquisition that helps them move into hips, knees and ankles. There is volatility. He would enter around $205-210. (Analysts’ price target is $230.25)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
January 17, 2020
A diversified medical devices company. They create a variety of equipment, including orthopaedics and robotic surgery. The company has executed very well. They recently made an acquisition that helps them move into hips, knees and ankles. There is volatility. He would enter around $205-210. (Analysts’ price target is $230.25)
biotechnology/pharmaceutical
0 Comments
Paul MacDonald

Unlock Ratings

Price
$212.170
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
December 19, 2019
Good demographic growth--people are getting older and need hip and knee replacement. They just bought a company that will make SYK the biggest company serving hands and ankles. Another plus is that doctors tend to stick with the same medical product manufacturers. They have $3 billion in free cash and pays a nice dividend. They constantly buy companies, but their debt is fine. (Analysts’ price target is $231.08)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
December 19, 2019
Good demographic growth--people are getting older and need hip and knee replacement. They just bought a company that will make SYK the biggest company serving hands and ankles. Another plus is that doctors tend to stick with the same medical product manufacturers. They have $3 billion in free cash and pays a nice dividend. They constantly buy companies, but their debt is fine. (Analysts’ price target is $231.08)
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$208.080
Owned
Yes
DON'T BUY
DON'T BUY
Stryker Corp. (SYK-N)
December 18, 2019

SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
December 18, 2019

SYK vs. JNJ SYK makes medical products while JNJ also produces that plus pharma and personal care products, but are fighting talcum powder lawsuits that will persist. Despite this, he much prefers JNJ due to better diversification and valuation. But wait for a better entry point.

biotechnology/pharmaceutical
0 Comments
Lorne Steinberg

Unlock Ratings

Price
$208.520
Owned
Unknown
BUY
BUY
Stryker Corp. (SYK-N)
November 27, 2019
Diversified in orthopedics and medical instruments. Zimmer falling on hard times has been to its benefit. Not that expensive, around 20x earnings. Likes it.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
November 27, 2019
Diversified in orthopedics and medical instruments. Zimmer falling on hard times has been to its benefit. Not that expensive, around 20x earnings. Likes it.
biotechnology/pharmaceutical
0 Comments
Gordon Reid

Unlock Ratings

Price
$204.940
Owned
No
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
November 7, 2019
(A Top Pick Nov 20/18, Up 22%) Demographically, in a great spot. Recent acquisition will expand their market. Developing robotics. Positive long-term.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
November 7, 2019
(A Top Pick Nov 20/18, Up 22%) Demographically, in a great spot. Recent acquisition will expand their market. Developing robotics. Positive long-term.
biotechnology/pharmaceutical
0 Comments
Zachary Curry

Unlock Ratings

Price
$200.780
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
October 28, 2019
They don't have the patent cliffs that the drugs are going to come off, and they will continue to innovate. Aging demographics will help demand. He's happy to hold this.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
October 28, 2019
They don't have the patent cliffs that the drugs are going to come off, and they will continue to innovate. Aging demographics will help demand. He's happy to hold this.
biotechnology/pharmaceutical
0 Comments
Brett Girard, CPA, CA, CFA

Unlock Ratings

Price
$213.720
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
July 17, 2019
One of his favourite medtech names. They lead in robotic surgery. Great organic growth. They're setting up for a great quarter.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
July 17, 2019
One of his favourite medtech names. They lead in robotic surgery. Great organic growth. They're setting up for a great quarter.
biotechnology/pharmaceutical
0 Comments
Paul MacDonald

Unlock Ratings

Price
$207.950
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
June 27, 2019
The medical device sector has been a leading group for the last three years and he has been a big proponent. They are interesting because it is secular growth. Demographics support what these companies are doing. They are very defensible because they are not tied to the economic cycle. So long as growth performs well, he likes this group. He owns it through the medical devices ETF.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 27, 2019
The medical device sector has been a leading group for the last three years and he has been a big proponent. They are interesting because it is secular growth. Demographics support what these companies are doing. They are very defensible because they are not tied to the economic cycle. So long as growth performs well, he likes this group. He owns it through the medical devices ETF.
biotechnology/pharmaceutical
0 Comments
David Burrows

Unlock Ratings

Price
$202.540
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
June 21, 2019
(A Top Pick Aug 17/18, Up 20%) Hips and knees. Robots doing knee surgery. 3D replacements for hips. Continues to chug along. Growing revenue 6-7%.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 21, 2019
(A Top Pick Aug 17/18, Up 20%) Hips and knees. Robots doing knee surgery. 3D replacements for hips. Continues to chug along. Growing revenue 6-7%.
biotechnology/pharmaceutical
0 Comments
David Driscoll

Unlock Ratings

Price
$202.720
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
June 4, 2019

Medical devices in a great demographic growth area. They are developing robotics to assist in surgery. Think of it as a med-tech company. Yield 1.1% (Analysts’ price target is $201.12)

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 4, 2019

Medical devices in a great demographic growth area. They are developing robotics to assist in surgery. Think of it as a med-tech company. Yield 1.1% (Analysts’ price target is $201.12)

biotechnology/pharmaceutical
0 Comments
Zachary Curry

Unlock Ratings

Price
$186.450
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
May 21, 2019
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
May 21, 2019
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$185.450
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
May 3, 2019
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
May 3, 2019
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
biotechnology/pharmaceutical
0 Comments
Paul MacDonald

Unlock Ratings

Price
$190.710
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
April 22, 2019
Great company, trading cheap in the low-20's. It will do well as its competitors stumble.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
April 22, 2019
Great company, trading cheap in the low-20's. It will do well as its competitors stumble.
biotechnology/pharmaceutical
0 Comments
Gordon Reid

Unlock Ratings

Price
$182.160
Owned
Unknown
BUY
BUY
Stryker Corp. (SYK-N)
April 9, 2019
A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
April 9, 2019
A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.
biotechnology/pharmaceutical
0 Comments
Paul Harris, CFA

Unlock Ratings

Price
$195.970
Owned
No
Showing 1 to 15 of 77 entries
Next Page
© Stockchase Inc.